Texas Retina Associates
Quick facts
Marketed products
- Eylea · Oncology
Phase 2 pipeline
- Active bevacizumab and Active dexamethasone · Ophthalmology
This combination uses bevacizumab to inhibit vascular endothelial growth factor (VEGF) and reduce abnormal blood vessel formation, while dexamethasone suppresses inflammation in the eye.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: